Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Breast Neoplasms 34Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Prostatic Neoplasms 2Neoplasms by Site 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Solid Tumors 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor, Adult 1Neoplasm Metastasis 1Melanoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Fulvestrant × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡